
Disapproval from top shareholder throws $74bn BMS/Celgene merger into doubt
pharmafile | February 28, 2019 | News story | Sales and Marketing | Bristol-Myers Squibb, Celgene, acquisition, pharma
The news kicked off 2009 with a bang when Bristol-Myers Squibb announced it intended to acquire Celgene for $74 billion, but what could potentially be the biggest pharmaceutical industry merger of all time has been thrown into doubt thanks to a key BMS shareholder.
Top shareholder Wellington Management, which owns around 8% of BMS shares, has announced, in a rare move, that it does not support the prospective deal on the basis that it is a risky and expensive move. Celgene’s shares dropped by 8.5% following the news, but BMS shares rose 3% – the difference in share price between the two companies widened to almost 20%.
Activist hedge fund Starboard Value has been vocal in its opposition to the potential deal, canvassing its shareholders and filing a slate of nominees in a bid to put a stop to it. Analysts believe Wellington Management’s announcement could embolden this stance, and lead other shareholders to voice their disapproval for the deal.
However, BMS remained optimistic and determined: “We believe that we are acquiring Celgene at an attractive price, and that this transaction presents an important and unique opportunity to create sustainable value.”
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Brenntag acquires mcePharma to expand GMP capabilities in biopharma services
Brenntag Specialties has acquired Czech-based mcePharma, strengthening its position in the pharma and biopharma industries …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …






